Results 11 to 20 of about 466,117 (305)

Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer

Chinese Medical Journal, 2020
. Increasing numbers of targeted drugs are used in hormone receptor (HR)-positive metastatic breast cancer (MBC) to overcome or delay resistance to endocrine therapy.
Li Bian, Feng-Rui Xu, Ze-Fei Jiang, Qiang Shi   +3 more
doaj   +1 more source

DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation [PDF]

, 2015
The acquisition of endocrine therapy resistance in estrogen receptor a (ERa) breast cancer patients represents a major clinical problem. Notch signalling has been extensively linked to breast cancer especially in patients who fail to respond to endocrine
Aifantis, Apatira, Apweiler, Brennan, Carroll, Chazotte, Chen, Coombes, Darbre, Eikesdal, Forgac, Goloubeva, Gul, Hill, Ho, Joffe, Johnston, Jones, Jones, Jones, Kane, Kang, Kocak, Lake, Le Borgne, Lendahl, Liu, Lupien, Mader, Mao, Martinez, McPherson, Medici, Meyer, Miele, Miele, Miele, Miyamoto, Nguyen, Nicolson, Roegiers, Sarkar, Schiff, Schilling, Schupbach, Sutherland, Taylor, Urbe, Vaccari, Venkanteshan, Wang, Webster, Wieczorek, Wong, Zahler   +54 more
core   +3 more sources

The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer

Frontiers in Endocrinology, 2023
Endocrine therapy is the prominent strategy for the treatment of hormone-positive breast cancers. The emergence of resistance to endocrine therapy is a major health concern among hormone-positive breast cancer patients.
Jie Yuan, Jie Yuan, Li Yang, Zhi Li, Hua Zhang, Qun Wang, Jun Huang, Bei Wang, Chakrabhavi Dhananjaya Mohan, Chakrabhavi Dhananjaya Mohan, Gautam Sethi, Geng Wang   +11 more
doaj   +1 more source

Treatment of symptoms of the menopause: an endocrine society clinical practice guideline [PDF]

, 2015
Objective: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. Participants: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and
Davis, Susan R., Gompel, Anne, Lumsden, Mary Ann, Murad, M. Hassan, Pinkerton, JoAnn V., Santen, Richard J., Stuenkel, Cynthia A.   +6 more
core   +1 more source

Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer

Cancer Cell International, 2021
Drug resistance is always a great obstacle in any endocrine therapy of breast cancer. Although the combination of endocrine therapy and targeted therapy has been shown to significantly improve prognosis, refractory endocrine resistance is still common ...
Jing Chen, Runlan Wan, Qinqin Li, Zhenghuan Rao, Yanlin Wang, Lei Zhang, Alexander Tobias Teichmann   +6 more
doaj   +1 more source

CDK4/6 inhibition in luminal breast cancer [PDF]

, 2016
Endocrine therapy represents the basis for the treatment of estrogen receptor-positive breast cancer, but several tumors harbor intrinsic resistance and acquired resistance to endocrine therapy is inevitable in metastatic disease.
Gabriel Rinnerthaler, Richard Greil, Simon Peter Gampenrieder   +2 more
core   +1 more source

Improvement of Pig Islet Function by In Vivo Pancreatic Tissue Remodeling: A “Human-Like” Pig Islet Structure with Streptozotocin Treatment

Cell Transplantation, 2013
Pig islets demonstrate significantly lower insulin secretion after glucose stimulation than human islets (stimulation index of ~12 vs. 2 for glucose 1 and 15 mM, respectively) due to a major difference in β- and α-cell composition in islets (60% and 25 ...
Sophie Vériter, Najima Aouassar, Gwen Beaurin, Rose-Marie Goebbels, Pierre Gianello, Denis Dufrane Ph.D.   +5 more
doaj   +1 more source

Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells [PDF]

, 2017
Purpose: Early detection is essential for treatment plans before onset of metastatic disease. Our purpose was to demonstrate feasibility to detect and monitor estrogen receptor 1 (ESR1) gene mutations at the single circulating tumor cell (CTC) level in ...
Austin, Laura, Capoluongo, Ettore, Cristofanilli, Massimo, Fortina, Paolo, Knudsen, Karen E., Mu, Zhaomei, Nguyen, Thomas, Paolillo, Carmela, Rossi, Giovanna, Schiewer, Matthew J.   +9 more
core   +3 more sources

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review

Therapeutic Advances in Medical Oncology, 2017
We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer.
Tomás Reinert, Carlos H. Barrios
doaj   +1 more source

Early discontinuation of endocrine therapy for breast cancer: Who is at risk in clinical practice? [PDF]

, 2014
Purpose: Despite evidence supporting at least five years of endocrine therapy for early breast cancer, many women discontinue therapy early. We investigated the impact of initial therapy type and specific comorbidities on discontinuation of endocrine ...
45 and Up Study Collaborators, A Coates, A Kemp, A Kemp, A Partridge, AH Partridge, AI Neugut, ATAC Trialists’ Group, Australian Bureau of Statistics, Australian Government Department of Health, Australian Government Department of Health, Australian Population and Migration Research Centre, C Davies, C McCowan, C Murphy, C Owusu, CC Earle, Centre for Health Record Linkage (CHeReL), DL Hershman, EA Grunfeld, EB Lamont, EP Winer, G Kimmick, G Viale, JB Bell, JF Forbes, JM Bliss, K Chim, K Weaver, K-P Hsieh, KL Cheung, L Fallowfield, L Huiart, L Nekhlyudov, M Baum, M Stokes, ME Charlson, MP van Herk-Sukel, MU Yood, NBCC, Organisation for Economic Co-operation and Development, R Sedjo, S Demissie, S Sehdev, Swedish Breast Cancer Cooperative Group, TI Barron, U Güth, VC Jordan   +47 more
core   +3 more sources